Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-label, Safety and Tolerability Trial of Intravenous Obrixtamig in Combination With Pumitamig and Standard of Care (Carboplatin, Etoposide) in Patients With Extensive-stage Small Cell Lung Carcinoma

NCT07843940 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07843940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07843940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-label, Safety and Tolerability Trial of Intravenous Obrixtamig in Combination With Pumitamig and Standard of Care (Carboplatin, Etoposide) in Patients With Extensive-stage Small Cell Lung Carcinoma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 1, 2026
Completion date
April 21, 2030
Enrollment
55 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

advanced small cell lung cancer, extensive-stage small cell lung carcinoma